

Patent Applicati

Attorney Docket No.PC11812ACA I hereby certify that this correspondence is being deposited with the United States Postal Service as I to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 3rd day of June ature of person mailing Erica L. Smith (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: Robert L. Dow, et al. **APPLICATION NO.: 10/086,588** Examiner: Group Art Unit: 1614 FILING DATE: February 28, 2002 TITLE: Beta 3 Agonists and Uses Thereof Hon. Commissioner for Patents Washington, D.C. 20231 Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Pursuant to 37 C.F.R. 1.97(b)(3); and 1.98, Applicant's agent wishes to draw the Examiner's attention to PTO-FB-A820 which lists the reference cited by the applicant, a copy of which is enclosed.

The Examiner is respectfully requested to indicate his or her consideration of the foregoing item by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. This information disclosure statement is being submitted prior to receiving a first office action; therefore, no fee is required. In the event that an office action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-0871

Respectfully submitted,

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

JUN 0 6 2002 S

I.L. IVED

JUN 1 1 2002

TECH CENTER 1600/2900 INFORMATION SCLOSURE CITATION SERIAL NO. 10/086,588 ATTY. DOCKET NO. PC11812AAKM

(Use s	everal si	heets if	necessa	ary)	AP	PLICAN	T Ro	bert L. Dov	w, et al.			
						FILING DATE February 28, 2002 GROUP 1614						
	_				U.S	. PATEN	IT DOC	UMENTS				
AMINER NITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING D
	5	9	7	7	1	2	4	11/2/99	Dow	514	272	
	5	7	7	6	9	8	3	7/7/98	Washburn, et a	i. 514	605	
	5	0	3	0	6	4	0	7/9/91	Fisher, et al.	514	339	
	5	0	1	9	5	7	8	5/28/91	Fisher, et al.	514	275	
	4	4	7	8	8	4	9	10/23/84	Ainsworth, et a	l. 424	285	
	4	3	5	8	4	5	5	11/9/82	Atkinson, et al	. 424	263	
	5	1	5	3	2	1	0	10/6/92	Ainsworth, et a	l. 514	369	
	5	7	0	5	5	1	5	1/6/98	Fisher, et al.	514	365	
	5	7	9	2	8	7	11	8/11/98	Chartrain, et a	l. 546	335	
					FORE	GN PAT	ENT D	OCUMENT	rs 		Т	
	DOCUMENT NUMBER							DATE	DATE COUNTRY		SUBCLASS	TRANSLA
	-T	1		1	T	T						YES
EP	0_	5	1	6	3	4	9	12/2/92	European	C07C	217/18	<u> </u>
wc	9	9	6	5	8	7	7	12/23/99	International	C07D	213/80	
wo	0_	2	0	6	2	7	4	1/24/02	International	C07D	401/12	
		ОТН	ER DO	CUMEN	TS (Ind	cluding A	luthor, T	itle, Date,	Pertinent Page	es, Etc.)		
		mariam, (1994).	B. et al.,	"β1 – and	β2-Adre	enoceptor	Antagonis	st Activities o	of ICI-215001, a P	utative β3-Adro	enoceptor A	gonist",
								3611A and Bf 311-1316 (19	RL 37344, and of \$ 993).	Salbutamol on	Cholinergic	and NA
	Phen	ylethanola	aminotetra	alines" , 44	<b>1</b> , 1411-1	1417 1989)	).		s of New Gut-Spec			
	Simia 201 1		, "Antidepi	essant Pr	ofile In F	Rodents of	SR 5861	IA, a New Se	elective Agonist for	· Atypical β-adı	renoceptors"	, 219, 19
			"Evidence uinea Pig"				ition to « /	Atypical » Bet	ta Adrenoceptors (	or Putative Be	ta-3 Adreno	ceptors)
1 1	Vriot	etal "Ti	ssue Distr	ibution of	ß3-adre	neraic Rec	eptor mR	NA in Man". 9	<b>91</b> 344-349 (1993)	) <u>.</u>		
	Kilei,	Ct ai., Ti								·		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with